Kornimate/medical-research-clean huggingface dataset:
sexual hepatitis c in hiv positive men who have sex with men (msm) in bordeaux

Conditions: Human Immunodeficiency Virus (HIV); Hepatitis c

Summary: the main objective of this study is to analyse sexual behavior of hiv + msm in bordeaux, who have sexually contracted hepatitis c between january 1st 2013, to january 31, 2017. these data will bring some improvement about prevention and maybe reduced the hepatitis c incidence.

hepatitis c (hcv) is considered in part as a sexually transmitted infection (sti). a marked decrease in its incidence has been observed for several years, coinciding with the availability of new direct acting antiviral treatments (daa). however, people are increasingly infected with the hepatitis c virus, especially hiv-positive msm. this increase is explained by new sexual practices that are particularly at high level of risk, despite the widening accessibility of new daa. prevention also plays an important role in implementing an effective risk reduction policy. new methods of prevention must therefore be developed. for this purpose, it is imperative to know the natural history of acute hepatitis c, the different behaviours at risk of hcv transmission, and the demonstration of socio-sexual networks (clusters) thanks to virological phylogenetic studies. in order to improve hepatitis c prevention, we wish to establish a descriptive study focusing on : * descriptive analysis of the natural history of hepatitis c, * identification of patient clusters (phylogenetic analysis) * description of the sexual behaviors of infected patients, through a semi-directed interview.

Eligibility criteria:
inclusion criteria: * patient older than 18 years * hiv-1 and/or hiv-2 confirmed infection * men who have sex with men * patients included in the "anrs co3aquitaine cohort". * hcv contamination documented over the period 01/01/2013 to 01/31/2017 (a positive hcv serology and a hcv plasma rna positive) and a negative hcv serology or a positive hcv serology and a negative plasma rna before inclusion period * a person who has received information about the protocol and has given oral consent and that his / her non-opposition is documented in his / her medical file. exclusion criteria: * transfusion contamination * substance abuse iv out of slam context * refusal to consent to research.

Keywords: hepatitis c sexual network sexual transmitted men who have sex with men hiv positive sexual behaviour
effectiveness of telerehabilitation in total knee arthroplasty

Conditions: Knee Osteoarthritis; Total Knee Arthroplasty

Summary: in patients who have had joint replacement surgery, there is a shortage of concrete evidence regarding the effectiveness of telerehabilitation. the aim of this study is to compare telerehabilitation with home based exercise program and standard home exercise program in total knee arthroplasty.

the primary aim of our study is to assess the effectiveness of telerehabilitation in comparison to the conventional approach, specifically focusing on particular parameters, in the context of post-total knee arthroplasty surgery. this investigation will entail a comparative analysis between a home exercise program prescription supplemented with visual and video resources using telerehabilitation and the conventional home exercise program prescription. the aim of our study is comparison between two exercise prescription modalities : a standard home exercise program and an internet-based program utilizing the rehab my patient software with visual and video support, in addition to telerehabilitation program, which involves exercise prescription oversight via video consultations. this comparison will include the following parameters : range of motion, proprioception , function, kinesiophobia, pain , patient adherence, patient satisfaction and quadriceps muscle strength.

Eligibility criteria:
inclusion criteria: * participants aged 50 and over * having a primary total knee arthroplasty surgery * to possess a device, such as a smartphone or tablet, that enables access to mobile applications. * to have the capability to use the internet and to have internet access. * proficiency in reading and writing in the turkish language * having a mini-mental state examination(mmse) score of 24 or higher * to be willing to participate in the study exclusion criteria: * having cognitive problem * having a secondary total knee arthroplasty surgery * havig a revision surgery * having a history of cerebrovascular and/or cardiovascular events in the last 3 months * having uncontrolled diabetes and/or hypertension * having a arthrogenic muscle inhibition

Keywords: total knee arthroplasty telerehabilitation home exercise osteoarthritis orthopaedic rehabilitation
reducing hemarthrosis in acl reconstruction with btb autograft by the administration of intravenous txa

Conditions: Anterior Cruciate Ligament Reconstruction

Summary: the purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (txa) to patients undergoing anterior cruciate ligament (acl) reconstruction with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and post operative pain.

the purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (txa) to patients undergoing anterior cruciate ligament (acl) reconstruction with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and post operative pain. patients received the standard arthroscopic acl reconstruction with a btb autograft and were randomized to either receiving or not receiving two individual doses of txa intra-operatively or receive. the goal of the study is to determine and evaluate the effect of intra-operative txa on post-operative hemarthrosis, pain reduction, and opioid consumption.

Eligibility criteria:
inclusion criteria: -patients undergoing an acl reconstruction with btb autograft exclusion criteria: * legally incompetent or mentally impaired (e.g., minors, alzheimer's subjects, dementia, etc.) * younger than 18 years of age * any patient considered a vulnerable subject * have bleeding or clotting disorder * preoperative anticoagulation therapy * abnormal coagulation profile * renal disorder or insufficiency * sickle cell disease
a study of bms-986484 alone and combination therapy in participants with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to assess the safety and tolerability of bms-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (nsclc), microsatellite stable (mss) colorectal carcinoma (crc), pancreatic ductal adenocarcinoma (pdac), gastric/gastroesophageal junction adenocarcinoma (g/gejc), and squamous cell carcinoma of the head and neck (scchn).


Eligibility criteria:
inclusion criteria: * locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (nsclc), pancreatic ductal adenocarcinoma (pdac), gastric/gastroesophageal junction adenocarcinoma (g/gejc), microsatellite stable colorectal cancer (mss crc), and squamous cell carcinoma of the head and neck (scchn). * must have measurable disease by response evaluation criteria in solid tumors version 1.1 (recist v1.1). * must have an eastern cooperative oncology group performance status of 0 or 1. exclusion criteria: * history of or with active interstitial lung disease or pulmonary fibrosis. * active, known, or suspected autoimmune disease. * serious uncontrolled medical disorders. * new onset, non-catheter-associated venous thromboembolism within the past 6 months. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: opdivo® immunotherapy bms-986484 non-small cell lung cancer (nsclc) microsatellite stable (mss) colorectal carcinoma (crc) pancreatic ductal adenocarcinoma (pdac) gastric/gastroesophageal junction adenocarcinoma (g/gejc) squamous cell carcinoma of the head and neck (scchn) anti-cd40 anti-fap
prevention of chop-induced chronic cardiotoxicity

Conditions: Non-Hodgkin's Lymphoma

Summary: the purpose of this study is to assess the protective effect of valsartan on chronic cardiotoxicity induced by chop.

doxorubicin has been one of the most important key drugs in treatment for malignancies. however, its use is limited by dose-dependent cumulative cardiotoxicity. this multi-centers trial was designed to investigate the preventive effect of valsartan, the angiotensin ii type 1 receptor blocker (arb) on chronic cardiotoxicity due to doxorubicin based chemotherapy. patients with untreated non-hodgkin's lymphoma who are scheduled to receive at least 6 courses of the standard chop (-r) will be randomized by the minimization methods to the treatment group with valsartan (80mg once daily by oral during entire 6 courses of chop) or control group. cardiac function will be evaluated in detail before and after 3 and 6 courses of chop (-r).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of non-hodgkin's lymphoma (nhl) * untreated lymphoma * performance status from 0 to 1, * total serum bilirubin \< 2.0 mg/dl * serum creatinine level \< 2.0 mg/dl * ejection fraction of the left ventricle \>50 % * systolic blood pressure at rest being 90 mmhg or more exclusion criteria: * severe complication including chronic or acute heart failure, angina, old myocardial infarction, liver cirrhosis, and interstitial pneumonia * pregnancy, nursing mothers or women of child-bearing potential * hypertension under medication * diabetes mellitus under medication * hyperthyroidism, nephrotic syndrome, cushing's syndrome * atrial arrythmias * severe psychopathy * cerebrovascular accidents within the past 3 months * positive serum hbs antigen or hcv antibody * a history of renal failure * a contraindication to a-ii antagonists or noncompliance * treatment with any of the following drugs within the past 3 months : a-ii antagonists, ace inhibitors, vitamin e, probucol, calcium antagonists, beta-blockers, and steroid pulse therapy.

Keywords: untreated adult non-hodgkin's lymphoma chop protocol angiotensin ii type 1 receptor blockers cardiomyopathy
mechanisms of action of photo(chemo)therapy in skin diseases

Conditions: Psoriasis; Cutaneous T Cell Lymphoma; Lymphoproliferative Disorders; Eczema; Lichen Planus; Prurigo; Pruritus; Polymorphic Light Eruption; Graft Vs Host Disease; Mastocytosis; Vitiligo

Summary: the molecular mechanisms of action of photo(chemo)therapy in skin diseases are investigated in this study. the phototherapeutic modalities employed include uvb (ultraviolet b), uva (ultraviolet a), puva (psoralen+uva) and/or extracorporeal photochemotherapy (photopheresis). the study will address whether and how photo(chemo)therapy affects specific biologic pathways in different skin disorders and search for predictive biomarkers.

this study is performed in order to investigate the molecular mechanisms of action of photo(chemo)therapy in skin diseases, including psoriasis, cutaneous t-cell lymphoma, other lymphoproliferative disorders of the skin, eczema, lichen planus, prurigo/pruritus, polymorphic light eruption, mastocytosis, graft-versus-host disease, vitiligo and other photo(chemo)therapy-responsive diseases. twenty patients will be enrolled per diagnosis group. the phototherapeutic modalities administered will be uvb, uva, puva and/or extracorporeal photochemotherapy (photopheresis). the severity of disease and clinical response to treatment will be assessed with scores including dermatological quality of life (dlqi) and disease-specific scores such as pasi (psoriasis area and severity index), mswat (modified severity-weighted assessment tool), scorad (scoring atopic dermatitis), scleroderma score and/or different visual analog scale (vas) scores for pruritus. the effect of treatment on a variety of laboratory endpoints will be investigated in blood samples and optionally also skin samples. those endpoints include among others the regulation of cytokines/chemokines, immune function, clonality of immune cells, vitamin d, and serum lipids. the study will address whether and how photo(chemo)therapy affects specific biologic pathways in the different disorders and determine whether predictive biomarkers for therapeutic response exist.

Eligibility criteria:
inclusion criteria: * age \> 18 years * skin disorder to be treated with photo(chemo)therapy exclusion criteria: * pregnancy and breastfeeding * poor general health status
effect of fenugreek use in mothers of preterm on breast milk production and macronutrient content

Conditions: Preterms; Lactation

Summary: feeding human milk to preterm infants does reduce the risk of serious and costly neonatal intensive care unit acquired morbidity such as nec and the late onset sepsis. it is often difficult to obtain sufficient quantities of human milk from mothers of preterm infants most of whom are breast pump-dependent for weeks or months. mothers will try to use galactogogues in an attempt to increase milk production. fenugreek (trigonella foenum-graecum) seeds is the most commonly used herbal galactogogue and is a member of the pea family. our experience at the nicu is that around 30% of preterm mothers desperately looking for ways to increase their breast milk supply will eventually took fenugreek (hilbe) as food supplement. although widely recommended, there is limited evidence to support the effectiveness of fenugreek as a galactogogue. the aims of this study are to evaluate whether maternal consumption of fenugreek seeds has any effect on macronutrients composition of breast milk and whether fenugreek is transferred to the infant via mother milk. in addition any changes in mother and infant health status will be assessed.


Eligibility criteria:
inclusion criteria: * healthy mothers 7 to 14 days postpartum, * mothers of preterm infants under 38 weeks of gestation, * mothers with poor milk supply documented by professional lactation consultants. exclusion criteria: * mothers with mastitis, * mothers with breast engorgement, * mothers currently consuming reglan, domperidone or other drugs/herbals used to induce milk production, * mothers who are taking medications (diuretics, pseudoephedrine, - anticholinergics, warfarin or any anticoagulant, an estrogen-containing birth control pill), * mothers with diabetes mellitus, * mothers who have had breast surgery that could alter milk synthesis or production, * mothers diagnosed with polycystic ovary syndrome, * mothers diagnosed with asthma or atopic disease, * mothers who are known to be allergic to peanuts or soybeans, * mothers whose milk supply per 24 hours exceeds 600 ml, * mothers with hypo/hyperthyroidism

Keywords: preterms breastfeeding lactation macronutrients
measurement of cytokines (il-1α) after shear- force application at the skin

Conditions: Pressure Ulcers, Bedsores, Decubitus Ulcer

Summary: background: a pressure ulcer is localized tissue injury to the superficial layer of the skin and/ or the underlying tissue. pressure ulcers are most likely to develop in skin areas exposed to pressure, shear and friction. shear- force is an important contributing factor and wound dressing are possibly capable to reduce shear force at the skin. at this moment there's no good marker to detect the effect of shear- force at the skin. a potential marker could be cytokines (il-1α) which are released after mechanical loading of the skin. a previous study have shown a significant increased level of il-1α after the application of pressure. we want to investigate if these cytokines are significant increased after the application of shear- force at the skin. objective: the objective of this study is to gather knowledge about cytokine concentrations (il-1 α) in the skin of healthy volunteers after the application of shear- force. we want to use this knowledge in the future to investigate if different prophylactic wound dressings are capable to reduce shear force at the skin. this could be interesting in the prevention of pressure ulcers. study design: with the use of a special developed shear- force model are we going to administer 20 newton (2 kg) shear at the palmar side of the under arm in 10 healthy volunteers for 30 minutes. as a control we ware going to put the shear- force model at the other arm without the application of shear- force. before the use of the shear- force model we will perform cytokine measurements with the use of sebutape. sebutape is capable to absorb cytokines from the skin. after the use of the shear force- model we will perform cytokine measurements again. then we will extract the cytokines from the sebutape with the use of elisa. study population: 10 healthy volunteers age 18- 30 years primary outcome: il-1 α concentration (pg/ml)


Eligibility criteria:
inclusion criteria: * age 18- 30 years * bmi 20 -30 * braden score \> 20 exclusion criteria: * trauma arms * skin diseases (eczema, psoriasis) * inability to give informed consent * muscle disorders * malignancy

Keywords: il-1 alpha, sebutape, shear- force
fimasartan in the senior subjects

Conditions: The Elderly (≥ 70 Years) With Essential Hypertension

Summary: the objective of this study is to confirm the noninferiority of the blood pressure lowering effect of fimasartan and evaluate its safety compared to perindopril in the elderly with essential hypertension.


Eligibility criteria:
inclusion criteria: 1. voluntarily provided a written consent to participate in this clinical study after receiving an explanation of this study 2. elderly aged 70 years or older 3. at the screening visit (visit 1), blood pressure: mean blood pressure measured 3 times on the selected arm is as below. * for treatment-naïve patients who have not taken drugs for hypertension within the last 3 months from the screening visit: mean sisbp ≥ 140mmhg * for patients with essential hypertension who are taking drugs for hypertension: mean sisbp ≥ 130mmhg 4. at the baseline visit (visit 2), blood pressure: patients with mild to moderate essential hypertension whose mean sisbp measured 3 times on the selected arm is ≥140 mmhg patients with treatment compliance of ≥70% during the placebo run-in period 5. capable of understanding written instructions, cooperative, able to participate until the end of the clinical study exclusion criteria: 1. severe hypertension patients with mean sisbp ≥ 180 mmhg or sidbp ≥ 110 mmhg (office bp) at the screening visit (visit 1) and the baseline visit (visit 2) (however, at screening, it is based on the blood pressures measured from both arms, and the patient is excluded if the result from any of the arms falls within the criteria.) 2. patients with sisbp ≥ 20 mmhg and sidbp ≥ 10 mmhg in the difference between blood pressures in the selected arm at the screening visit (visit 1) 3. patients with a history of secondary hypertension and any history suspected of secondary hypertension (but not limited to the following: coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc.) 4. orthostatic hypotension with symptoms 5. patients with insulin-dependent diabetes mellitus or uncontrolled diabetes mellitus (hba1c \> 9.0% at the screening visit (visit 1)) 6. patients with a history of malignant tumor, including leukemia and lymphoma, within the past 5 years (however, participation is allowed if it has not recurred for at least 5 years after a tumor surgery) 7. patients with any chronic inflammatory disease requiring chronic anti-inflammatory treatment, consumption disease, autoimmune disease like rheumatoid arthritis and systemic lupus erythematosus, etc., or connective tissue disease at present or in the past 8. patients with a history of hypersensitivity reaction to any component of the investigational product and its similar compound renin-angiotensin system inhibitors, ace inhibitors, thiazide diuretics and sulfonamides, yellow 5 (sunset yellow fcf), etc. 9. patients with hyperlipidemia undergoing ldl (low density lipoprotein) apheresis (patients undergoing ldl hemapheresis using a dextran sulfate cellulose)
evaluation of outcomes of minimally invasive non- surgical versus surgical therapy in furcation involvement.

Conditions: Furcation Defects; Open Flap Debridement; Periodontal Diseases

Summary: the reduced rate of success experienced in the treatment of furcation involvement (fi) seems to result from the incomplete removal of subgingival plaque and calculus in the interradicular area owing to the peculiar anatomy of the furcation space. regarding the therapeutic approach, although fi treated with a conservative approach may not yield the same satisfactory results as single rooted teeth; it has been shown that teeth with fi have a remarkable survival rate following conservative treatment in patients demonstrating a satisfactory plaque control. minimally invasive techniques aim to retain the preoperative gingival architecture, create a minimal wound and gently handle soft and hard tissues. it becomes imperative to see the differences in clinical, and patient centered outcomes of minimally invasive non- surgical versus surgical technique in the management of furcation involvement in mandibulae molar.

patients will be recruited from outpatient clinic of department of periodontics, pgids, rohtak after screening based on given inclusion and exclusion criteria. after initial session of scaling and root planing patient will be re -elevated at the and of 6 to 8 weeks those having grade 2 furcation involvement in any mandibular molar and meeting other eligibility criteria will be randomly allocated to test group and control group test group -experimental sites designated to receive non-surgical treatment will be submitted to careful subgingival debridement using curettes and ultrasonic device using 3.5 x magnification. control group-surgical technique will be followed with minimally flap reflection and incisions will be performed with papilla preservation techniques. vertical- releasing incisions will not be made, and the full-thickness flap will be minimally elevated. the granulation soft tissue will be dissected with a blade and carefully removed with curettes. the visible calculus will be carefully removed with curettes and an ultrasonic device. the flaps will be re-positioned and sutured and patient follow up 3 to 6 months .

Eligibility criteria:
inclusion criteria: * systemically healthy patients with diagnosis of generalized stage 3 periodontitis (grade a or b) with at least one mandibular molar with fi (degree 1 or 2-according to hamp, 1975 and subclass a or b- according to tarnow and fletcher, 1984), interproximal bone coronal to the furcation fornix and root trunk length ≤ cervical two thirds of the root length as measured on a periapical radiograph. * full mouth plaque score \< 30% after initial therapy * full mouth bleeding score \< 30% after initial therapy * having undergone a course of subgingival instrumentation in the past three months exclusion criteria: * pregnant or lactating females * requiring antibiotic premedication * received antibiotic treatment in the previous 3 months * previous periodontal surgery in the last 1 year * smokers * pulpal or periapical pathology * third molar * non restorable tooth * trauma from occlusion